Key result
The combination of Angiopoietin-2 and NT-proBNP predicted pulmonary hypertension in COPD patients with an AUROC of 0.766, exceeding the predictive value of Angiopoietin-2 alone.
Why the study?
Effective treatment for pulmonary hypertension caused by COPD is not established, making prompt identification of patients with pulmonary hypertension particularly important.
Does Angiopoietin-2 combined with NT-proBNP predict the presence of pulmonary hypertension in patients with COPD?
Cohort
Does Angiopoietin-2 combined with NT-proBNP predict the presence of pulmonary hypertension in patients with COPD?
Angiopoietin-2 combined with NT-proBNP may be a useful biomarker panel for predicting pulmonary hypertension in patients with COPD.
Answers are grounded in this paper and cite their sources.
Angiopoietin-2 may support PH risk stratification in COPD; leaves open whether measurement improves outcomes or should guide therapy.
Clear and effective treatment for pulmonary hypertension (PH) caused by chronic obstructive pulmonary disease (COPD) has not been established, and thus promptly identifying patients with PH is of particular importance. In this study, by comparing Angiopoietin-2 expression in patients with COPD and COPD-PH, we analysed the risk factors of PH and evaluated the predictive value of these in PH. Therefore, this prospective study selected COPD of patients as research subjects, which were divided into COPD and COPD-PH groups according to whether they were complicated with PH. Lung function, general laboratory index, N-terminal pro brain b-type natriuretic peptide (NT-proBNP), Angiopoietin-2, and other cytokines levels were compared between the two groups, and the risk factors of COPD-PH were explored through multivariate binary regression analysis. Lastly, receiver operating characteristic curve was used in evaluating the predictive value of risk factors for COPD-PH. The results show that the COPD-PH group has higher Angiopoietin-2, logistic analysis showed that Angiopoietin-2, NT-proBNP, age, and FEV1%pred were independent risk factors for COPD-PH and had high predictive value for COPD-PH. The AUROC for Angiopoietin-2 and NT-proBNP for predicting COPD-PH were 0.646 and 0.751. When Angiopoietin-2 ≥ 39.55 pg/ml, NT-proBNP ≥ 134.03 pg/ml, the sensitivity for COPD-PH prediction was 44.7 and 93.6%, respectively, and the specificity rates were 83.1 and 49.2%, respectively. When Angiopoietin-2 was combined with NT-proBNP, enhanced the AUROC to 0.766, exceeding Angiopoietin-2 alone, which may be useful in the prediction of COPD-PH.
No takes yet. Share an insight, caveat, or question.
Ni et al. (2025) conducted a cohort in Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease. Angiopoietin-2 and NT-proBNP levels vs. COPD without pulmonary hypertension was evaluated on Prediction of COPD-PH (AUROC 0.766). The combination of Angiopoietin-2 and NT-proBNP predicted pulmonary hypertension in COPD patients with an AUROC of 0.766, exceeding the predictive value of Angiopoietin-2 alone.
Synapse has enriched 10 related papers. Consider them for comparative context: